20 -21 May 2020

MarketsandMarkets Virtual Conference on Liquid Biopsy ( Time Zone - CENTRAL EUROPEAN TIME (CET)

Understanding the potential of liquid biopsies

The advancement of delicate CTC and cfDNA identification led to innovations that has empowered the improvement of liquid biopsies with numerous clinical applications, including-screening for nearness of disease, patient stratification and treatment determination, monitoring treatment reaction and early diagnostics.

MarketsandMarkets Virtual Conference on Liquid Biopsy will unite the pioneers from Diagnostics organization, Experts from Pharmaceutical and Bio-Pharma companies, Researchers and professors from renowned universities to address the challenges in early detection of tumor cells and the potential of liquid biopsies to screen, monitor and treatment of the diseases.

WHAT TO EXPECT

Key Highlights

Identification of circulating biomarkers for early diagnosis
Challenges and advantages to the end-users
Advancement in treatment and monitoring of cancer
Clinical and non-clinical application of liquid biopsy
Recent developments in assays for liquid biopsy
Incorporation of Artificial intelligence and machine learning in liquid biopsy

Who Should Attend?

Hospitals- Diagnostics Department, Department of clinical oncology, Pathology Labs

Designation- Oncologist, Immunologist, Hematologist, pathologist, General Practitioners, Lab managers, Lab directors, Medical directors

Universities: Designation- Professors, Researchers, Associate professors in Cancer study

Pharma/Therapeutics: Designation- CEO, COO, Senior scientist in cancer and immunology, Research scientist in cancer, Personalized medicine individuals

Why Attend?

Best networking opportunities with industrial experts from all around the world
100+ experts attending
Interactive panel discussions with pioneers of the field
Platform to showcase/exhibit innovative technologies
Expand on existing organizations and make new networks with across industry and the scholarly community

CONFERENCE AGENDA

Day 1 Wed, 20-May-2020
Day 2 Thu, 21-May-2020

Welcome note from MarketsandMarket

Opening remarks from the Chairman

FUTURE OPPORTUNITIES AND CHALLENGES FOR USING LIQUID BIOPSY

Keynote Presentation - Viable Single Cell Analysis & Circulating Tumor Cells as Liquid Biopsy in Cancer

03:10 - 03:40 DR CATHERINE ALIXPANABIÈRES PhD- , Director of the Laboratory Rare Circulating Human Cells (LCCRH), l’Université et CHU de Montpellier, France, Europe

The importance of sensitivity for Residual Disease and Recurrence (RDR) testing

03:40 - 04:10 Antony Newton , VP Business Development, Inivata

Urine - The Next Generation Early Disease Biomarker Source

04:10 - 04:40 YOUHE GAO , Professor Department of Biochemistry and Molecular Biology, , Beijing Normal University

RECENT DEVELOPMENTS OF LIQUID BIOPSY IN CANCER DETECTION

High Quality Liquid Biopsies- Capture the molecular reality

04:40 - 04:55 IMEN EL AMOURI , Team Lead Liquid Biopsy Biobank, Indivumed

Liquid biopsy for ovarian cancer

04:55 - 05:10 JIANYU RAO, M.D, Vice Chair- Diagnostic Technology Innovation, Director-Cytopathology, Director-International Telepathology Dept. Pathology and Lab Med, UCLA, David Geffen School of Medicine

Emerging use of liquid biopsies as non-invasive biomarkers: current landscape and future perspectives

05:10 - 05:40 Dr Emmanouil Karteris, Head, CBCEL, London

One-to-one networking break

Closing remarks from chairman

Welcome note from MarketsandMarkets

Opening remarks from the Chairma

CLINICAL APPLICATION OF LIQUID BIOPSY AND ASSAYS AVAILABILITY

Keynote Presentation – Blood-based brain injury biomarkers as theranostic tool to accelerate drug development

03:10 - 03:40 Kevin Wang, Director, Program for Neuroproteomics and Biomarkers Research, University of Florida

Liquid biopsy of cancer: a multimodal diagnostic tool in clinical oncology

03:40 - 04:10 Karl J. DSilva, Medical Director, Clinical Asst. Professor of Medicine, Tufts University School of Medicine, Lahey Hospitals and Medical Center

FNIH Biomarkers Consortium development of Quality Control Materials for ctDNA Assays

04:10 - 04:40 Dana E. Connors, Senior Scientific Project Manager, Cancer Foundation for the National Institutes of Health

FUTURE OPPORTUNITIES AND CHALLENGES FOR USING LIQUID BIOPSY

Challenges in Using Liquid Biopsy in Clinic

04:40 - 05:10 Dr. Harsha Doddihal, Clinical researcher, Oncologist, Fortis Hospital

One-to-one networking break

Closing remarks from the Chairman

CONFERENCE SPEAKERS

Speakers

Karl J. DSilva

Karl J. DSilva

Medical Director, Clinical Asst. Professor of Medicine

Tufts University School of Medicine, Lahey Hospitals and Medical Center

Karl J. DSilva

Medical Director, Clinical Asst. Professor of Medicine

Tufts University School of Medicine, Lahey Hospitals and Medical Center

Dana E. Connors

Dana E. Connors

Senior Scientific Project Manager

Cancer Foundation for the National Institutes of Health

Dana E. Connors

Senior Scientific Project Manager

Cancer Foundation for the National Institutes of Health

Dr Emmanouil Karteris

Dr Emmanouil Karteris

Head

CBCEL, London

Dr Emmanouil Karteris

Head

CBCEL, London

Antony Newton

Antony Newton

VP Business Development

Inivata

Antony Newton

VP Business Development

Inivata

DR CATHERINE ALIXPANABIÈRES PhD-

DR CATHERINE ALIXPANABIÈRES PhD-

Director of the Laboratory Rare Circulating Human Cells (LCCRH)

l’Université et CHU de Montpellier, France, Europe

DR CATHERINE ALIXPANABIÈRES PhD-

Director of the Laboratory Rare Circulating Human Cells (LCCRH)

l’Université et CHU de Montpellier, France, Europe

Jennifer Whittington

Jennifer Whittington

Surgical Oncologist

Queens Hospital Cancer Center

Jennifer Whittington

Surgical Oncologist

Queens Hospital Cancer Center

Dr. Harsha Doddihal

Dr. Harsha Doddihal

Clinical researcher, Oncologist

Fortis Hospital

Dr. Harsha Doddihal

Clinical researcher, Oncologist

Fortis Hospital

YOUHE GAO

YOUHE GAO

Professor Department of Biochemistry and Molecular Biology,

Beijing Normal University

YOUHE GAO

Professor Department of Biochemistry and Molecular Biology,

Beijing Normal University

SPONSORS

Leading Partner

example-image — Inivata

example-image — RaDar

Sponsors & Exhibitors

example-image — Indivumed

PAST EVENT GALLERY